摘要
目的探讨原发性肝癌患者采用125Ⅰ粒子植入联合非规则肝切除加肝动脉置泵栓塞化疗的临床效果。方法从郑州大学人民医院2010年3月至2011年3月收治的原发性肝癌患者中选取68例为研究对象,随机分为观察组34例,对照组34例,对照组行非规则肝切除术结合肝动脉置泵栓塞化疗进行治疗,观察组在对照组基础上加用125Ⅰ粒子植入治疗,观察两组患者治疗效果,不良反应发生情况及远期生存情况。结果观察组治疗总有效率为94.12%,明显高于对照组73.53%;经1~3年随访结果显示,观察组治疗后1年、3年存活率分别为91.18%和73.53%,明显高于对照组;观察组治疗后生存质量明显优于对照组,差异有统计学意义(P<0.05),观察组不良反应发生率同对照组比较,无明显差异(P>0.05)。结论在原发性肝癌治疗中,行非规则肝切除术结合肝动脉置泵栓塞化疗基础上联合125Ⅰ粒子植入治疗,效果显著,能有效提高患者远期存活率,改善生存质量,且不会明显提高不良反应发生率。
Objective To probe into the clinical effects of treating primary liver cancer by combining irregular liver resection and hepatic artery embolism chemotherapy pump with ^125 I particle implantation. Methods Totally 68 patients suffering from the primary liver cancer who accepted treatment in our hospital from March 2010 to March 2011 were taken as research objects and they were divided into observation group and control group, with 34 patients in each group. In the control group, they were treated by irregular liver resection and hepatic artery embolism chemotherapy pump. In the observation group, on the basis of that in the control group, they were treated by ^125 I particle implantation. Then, the treatment effects, occurrence of adverse reactions and the long - term survival of two groups were observed. Results The whole effective rate of treatment in the observation group was evidently higher than that in the control group. Ac- cording to the follow - up visits from 1 year to 3 years, after one year and three years, the survival rate in the observation group was evidently higher than that in the control group. The living quality in the observation group was evidently better than that in the control group and the differences had statistical significance （P 〈 0. 05 ）. In addition, the occurrence rate of adverse reactions in the observation group did not have evident differences from that in the control group （ P 〉 0. 05）. Conclusion The clinical effect of treating primary liver cancer by combining irregular liver resection and hepatic artery embolism chemotherapy pump with ^125I particle implantation is evident, which can effectively improve the long - term survival rate of patients, improve living quality, and would not improve evidently the occurrence rate of adverse reactions. Thus, it should be promoted in clinical applications.
出处
《医药论坛杂志》
2015年第7期19-21,共3页
Journal of Medical Forum
关键词
原发性肝癌
联合治疗
临床效果
Primary liver cancer
Combination treatment
Clinical effects
